Literature DB >> 25787327

Development of a UC781 releasing polyethylene vinyl acetate vaginal ring.

Christopher McConville1, Ian Major, David R Friend, Meredith R Clark, R Karl Malcolm.   

Abstract

UC781 is potent, hydrophobic, non-nucleotide reverse transcriptase inhibitor (NNRTI) against the human immunodeficiency virus (HIV). UC781 is currently being investigated for use as a potential HIV microbicide. A study in rhesus macaques demonstrated that a 100-mg UC781-loaded silicone elastomer vaginal ring released limited amounts of UC781 into the vaginal fluid and tissue after 28 days. The reason for this was due to the hydrophobic nature and limited aqueous solubility of UC781. This study describes the manufacture of UC781-loaded polyethylene vinyl acetate (PEVA) vaginal rings, which have an improved in vitro release rate of UC781 when compared to UC781-loaded silicone elastomer vaginal rings. The study demonstrates that the UC781 in the PEVA rings is mostly in its amorphous form due to the rings being manufactured above UC781's melting point. Furthermore, the rings do not show any signs of UC781 degradation, such as the presence of UC22.

Entities:  

Year:  2012        PMID: 25787327     DOI: 10.1007/s13346-012-0101-3

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  21 in total

1.  Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings.

Authors:  R Karl Malcolm; A David Woolfson; Clare F Toner; Ryan J Morrow; Stephen D McCullagh
Journal:  J Antimicrob Chemother       Date:  2005-09-09       Impact factor: 5.790

2.  Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.

Authors:  Hans-Joachim Ahrendt; Israel Nisand; Carlo Bastianelli; Maria Angeles Gómez; Kristina Gemzell-Danielsson; Wolfgang Urdl; Birgit Karskov; Luc Oeyen; Johannes Bitzer; Geert Page; Ian Milsom
Journal:  Contraception       Date:  2006-09-27       Impact factor: 3.375

3.  Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.

Authors:  D L Patton; Y T Cosgrove Sweeney; J E Balkus; L C Rohan; B J Moncla; M A Parniak; S L Hillier
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

4.  Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781.

Authors:  Ariela Zussman; Liliana Lara; Humberto H Lara; Zvi Bentwich; Gadi Borkow
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

5.  Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: results of clinical experience in Germany.

Authors:  C Brucker; U Karck; E Merkle
Journal:  Eur J Contracept Reprod Health Care       Date:  2008-03       Impact factor: 1.848

6.  Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.

Authors:  A David Woolfson; R Karl Malcolm; Ryan J Morrow; Clare F Toner; Stephen D McCullagh
Journal:  Int J Pharm       Date:  2006-06-23       Impact factor: 5.875

7.  Melt extrusion--an alternative method for enhancing the dissolution rate of 17beta-estradiol hemihydrate.

Authors:  S Hülsmann; T Backensfeld; S Keitel; R Bodmeier
Journal:  Eur J Pharm Biopharm       Date:  2000-05       Impact factor: 5.571

8.  Design of an intravaginal ring for the controlled delivery of 17 beta-estradiol as its 3-acetate ester.

Authors:  A D Woolfson; G R Elliott; C A Gilligan; C M Passmore
Journal:  J Control Release       Date:  1999-09-20       Impact factor: 9.776

9.  Design of a silicone reservoir intravaginal ring for the delivery of oxybutynin.

Authors:  A D Woolfson; R K Malcolm; R J Gallagher
Journal:  J Control Release       Date:  2003-09-04       Impact factor: 9.776

10.  A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging.

Authors:  L Henriksson; M Stjernquist; L Boquist; I Cedergren; I Selinus
Journal:  Am J Obstet Gynecol       Date:  1996-01       Impact factor: 8.661

View more
  4 in total

Review 1.  Vaginal drug delivery for the localised treatment of cervical cancer.

Authors:  Ian Major; Christopher McConville
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

Review 2.  The Vaginal Microbiota, Bacterial Biofilms and Polymeric Drug-Releasing Vaginal Rings.

Authors:  Louise Carson; Ruth Merkatz; Elena Martinelli; Peter Boyd; Bruce Variano; Teresa Sallent; Robert Karl Malcolm
Journal:  Pharmaceutics       Date:  2021-05-19       Impact factor: 6.321

3.  Development of Hormonal Intravaginal Rings: Technology and Challenges.

Authors:  Fojan Rafiei; Hadi Tabesh; Shayan Farzad; Farah Farzaneh; Maryam Rezaei; Fateme Hosseinzade; Khosrow Mottaghy
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-07-13       Impact factor: 2.915

Review 4.  Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.

Authors:  Fernando Notario-Pérez; Roberto Ruiz-Caro; María-Dolores Veiga-Ochoa
Journal:  Drug Des Devel Ther       Date:  2017-06-15       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.